World Library  
Flag as Inappropriate
Email this Article

Desmethylprodine

Article Id: WHEBN0000545765
Reproduction Date:

Title: Desmethylprodine  
Author: World Heritage Encyclopedia
Language: English
Subject: List of opioids, Synthetic opioids, Mu-opioid agonists, Drugs controlled by the German Betäubungsmittelgesetz, Piperidines
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Desmethylprodine

Desmethylprodine
Systematic (IUPAC) name
(1-Methyl-4-phenylpiperidin-4-yl) propanoate
Clinical data
Legal status
Identifiers
CAS Registry Number
PubChem CID:
DrugBank  Y
ChemSpider  Y
ChEMBL  Y
Synonyms 4-propionyloxy-4-phenyl-N-methylpiperidine, MPPP, 3-desmethylprodine
Chemical data
Formula C15H21NO2
Molecular mass 247.33 g/mol
 Y   

Desmethylprodine or 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP) is an opioid analgesic drug developed in the 1940s by researchers at Hoffmann-La Roche.[1] It is an analog of pethidine (meperidine) which the DEA has labeled as a Schedule I drug in the United States. Chemically, it is a reversed ester of pethidine which has about 70% of the potency of morphine.

Contents

  • History 1
    • Toxic impurity 1.1
  • Analogs 2
  • See also 3
  • References 4
  • External links 5

History

Desmethylprodine was first synthesized in 1947 at Hoffman-LaRoche Laboratories by Albert Ziering and John Lee. They found that it produced effects similar to morphine when administered to rats.[2] Ziering had been searching for synthetic painkillers that were less addictive than morphine. The new drug was a slight variant of pethidine. It was found to be no more effective than pethidine and was never marketed.[3]

In 1976, a 23-year-old graduate student in chemistry named Barry Kidston was searching for a way to make a legal recreational drug. Having read the paper by Ziering and Lee, he deduced that he could make a drug with pethidine's effects without its legal restrictions, since desmethylprodine is a different molecule and had never been addressed by law. Kidston successfully synthesized and used desmethylprodine for several months, after which he suddenly came down with the symptoms of Parkinson's disease and was hospitalized. Physicians were perplexed, since Parkinson's disease would be a great rarity in someone so young, but L-dopa, the standard drug for Parkinson's, relieved his symptoms. L-dopa is a precursor for dopamine, the neurotransmitter whose lack produces Parkinson's symptoms. It was later found that his development of Parkinson's was due to a common impurity in the synthesis of MPPP called MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin that specifically targets dopamine producing neurons. [3][4]

Toxic impurity

The intermediate tertiary alcohol is liable to dehydration in acidic conditions if the reaction temperature rises above 30 °C. Kidston did not realize this and esterified the intermediate with propionic anhydride at an elevated temperature. Consequently, MPTP was formed as a major impurity.[5]

1-Methyl-4-phenylpyridinium (MPP+), a metabolite of MPTP, causes rapid onset of irreversible symptoms similar to Parkinson's disease.[6][7] MPTP is metabolized to the neurotoxin MPP+ by the enzyme MAO-B, which is expressed in glial cells. This selectively kills brain tissue in the area of the brain called the substantia nigra and causes permanent Parkinsonian symptoms.[8]

Analogs

Structural analogs of desmethylprodine with different N-substituents than a methyl group on the piperidine have been investigated. Several of these have significantly greater in vitro potency compared to desmethylprodine.[9][10][11]

See also

References

  1. ^ U.S. Patent 2,765,314 - Preparation of Esters
  2. ^ Ziering, A.; Lee, J. (1947). "Piperidine derivatives; 1,3-dialkyl-4-aryl-4-acyloxypiperidines". The Journal of Organic Chemistry 12 (6): 911–914.  
  3. ^ a b Schwarcz, Joe (2005). "Aim high: synthetic opiates deliver surprising side effects". Canadian Chemical News 57 (10): 10. 
  4. ^ Gibb, Barry J. (2007). The Rough Guide to the Brain, Rough Guides Ltd., London, [2]
  5. ^ Johannessen, J. N.; Markey, S. P. (1984). "Assessment of the opiate properties of two constituents of a toxic illicit drug mixture". Drug and alcohol dependence 13 (4): 367–374.  
  6. ^ Davis, G. C.; Williams, A. C.; Markey, S. P.; Ebert, M. H.; Caine, E. D.; Reichert, C. M.; Kopin, I. J. (1979). "Chronic Parkinsonism secondary to intravenous injection of meperidine analogues". Psychiatry Research 1 (3): 249–254.  
  7. ^ Wallis, Claudia (2001-06-24). "Surprising Clue to Parkinson's - TIME". Time. Retrieved 2010-05-13. 
  8. ^ Schmidt, N.; Ferger, B. (2001). "Neurochemical findings in the MPTP model of Parkinson's disease". Journal of neural transmission (Vienna, Austria : 1996) 108 (11): 1263–1282.  
  9. ^ Elpern, B.; Wetterau, W.; Carabateas, P.; Grumbach, L. (1958). "Strong Analgesics. The Preparation of Some 4-Acyloxy-1-aralkyl-4-phenylpiperidines". Journal of the American Chemical Society 80 (18): 4916.  
  10. ^ Carabateas, P. M.; Grumbach, L. (1962). "Strong Analgesics. Some 1-Substituted 4-Phenyl-4-Propionoxypiperidines". Journal of Medicinal and Pharmaceutical Chemistry 5 (5): 913.  
  11. ^ Janssen, P. A.; Eddy, N. B. (1960). "Compounds related to pethidine-IV. New general chemical methods of increasing the analgesic activity of pethidine". Journal of medicinal and pharmaceutical chemistry 2: 31–45.  

External links

  • Desmethylprodine - PubChem
  • Street-Drug Contaminant causing Parkinsonism - June 22, 1984 warning from the CDC regarding MPTP byproduct in MPPP


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.